Preambolo 1
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing of plant protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC ( 1 ) , and in particular Article 20(1)(a) thereof,
Whereas:
HAS ADOPTED THIS REGULATION:
recital 1recital 1
(1) Commission Directive 2005/58/EC ( 2 ) included bifenazate as an active substance in Annex I to Council Directive 91/414/EEC ( 3 ) .
recital 2recital 2
(2) Active substances included in Annex I to Directive 91/414/EEC are deemed to have been approved under Regulation (EC) No 1107/2009 and are listed in Part A of the Annex to Commission Implementing Regulation (EU) No 540/2011 ( 4 ) .
recital 3recital 3
(3) The approval of the active substance bifenazate, as set out in Part A of the Annex to Implementing Regulation (EU) No 540/2011 expires on 31 July 2022.
recital 4recital 4
(4) An application for the renewal of the approval of the active substance bifenazate was submitted to the Rapporteur Member State in accordance with Article 1 of Commission Implementing Regulation (EU) No 844/2012 ( 5 ) within the time period provided for in that Article.
recital 5recital 5
(5) The applicant submitted the supplementary dossiers required in accordance with Article 6 of Implementing Regulation (EU) No 844/2012. The application was found to be complete by the rapporteur Member State.
recital 6recital 6
(6) The rapporteur Member State prepared a draft renewal assessment report in consultation with the co-rapporteur Member State and submitted it to the European Food Safety Authority (‘the Authority’) and the Commission on 29 January 2016.
recital 7recital 7
(7) The Authority made the supplementary summary dossier available to the public. The Authority also circulated the draft renewal assessment report to the applicant and to the Member States for comments and launched a public consultation on it. The Authority forwarded the comments received to the Commission.
recital 8recital 8
(8) On 4 January 2017, the Authority communicated to the Commission its conclusion ( 6 ) on whether bifenazate can be expected to meet the approval criteria provided for in Article 4 of Regulation (EC) No 1107/2009, where EFSA identified high risk to birds, mammals and non-target arthropods for all representative uses and in addition, a high risk to operators and workers for a majority of the representative uses. Furthermore, the risk assessment could not be finalised for aquatic organisms and consumers.
recital 9recital 9
(9) The Commission mandated EFSA in 17 November 2020 to assess the risk when bifenazate is applied once a year using the lowest dose presented in the dossier. The rapporteur Member State updated its draft Renewal Assessment Report accordingly and the Authority updated its conclusion on 30 August 2021 ( 7 ) in which it identified a high risk to birds via long term exposure to bifenazate for all representative uses. Furhtermore, the consumer risk assessment could not be finalised. The Commission presented a renewal report regarding bifenazate to the Standing Committee on Plants, Animals, Food and Feed on 19 July 2017 and 22 October 2021 and a draft of this Regulation on 1 December 2021.
recital 10recital 10
(10) The Commission invited the applicant to submit its comments on both conclusions of the Authority and, in accordance with the third paragraph of Article 14(1) of Implementing Regulation (EU) No 844/2012 ( 8 ) , on the renewal report. The applicant submitted its comments, which have been carefully examined.
recital 11recital 11
(11) It has been established with respect to one or more representative uses of at least one plant protection product containing the active substance bifenazate that the approval criteria provided for in Article 4 of Regulation (EC) No 1107/2009 are satisfied.
recital 12recital 12
(12) It is therefore appropriate to renew the approval of bifenazate.
recital 13recital 13
(13) In accordance with Article 14(1) of Regulation (EC) No 1107/2009 in conjunction with Article 6 thereof and in the light of current scientific and technical knowledge, it is, however, necessary to provide for certain conditions and restrictions. It is, in particular, appropriate to restrict the use of plant protection products containing bifenazate to non-edible crops in permanent greenhouses and to require further confirmatory information.
recital 14recital 14
(14) The restriction to use on non-edible crops will exclude dietary exposure of consumers and is required since the consumer risk assessment could not be finalised. As a high risk was identified to birds via long term exposure to bifenazate, a restriction to use in greenhouses as defined in Article 3 of Regulation (EC) No 1107/2009 will ensure that birds are not exposed to bifenazate. In addition, as the Authority identified a high risk to mammals for some representative uses and a high chronic risk to bees based on the available data, the restriction to use only in greenhouses will also prevent exposure to those non-target organisms as well as in drinking water.
recital 15recital 15
(15) As regards the criteria to identify endocrine disrupting properties introduced by Commission Regulation (EU) 2018/605 ( 9 ) , on the basis of the available scientific information summarised in the conclusion of the Authority, the Commission considers that bifenazate is not to be considered as having endocrine disrupting properties.
recital 16recital 16
(16) In order to increase the confidence in the conclusion that bifenazate does not have endocrine disrupting properties, the applicant should provide an updated assessment, in accordance with point 2.2(b) of Annex II to Regulation (EC) No 1107/2009, of the criteria laid down in points 3.6.5 and 3.8.2 of Annex II to Regulation (EC) No 1107/2009, and in accordance with the guidance for the identification of endocrine disruptors ( 10 ) .
recital 17recital 17
(17) The risk assessment for the renewal of the approval of the active substance bifenazate is based on representative uses as an acaricide. In the light of this risk assessment, it is not necessary to maintain the restriction to use only as an acaricide.
recital 18recital 18
(18) Implementing Regulation (EU) No 540/2011 should therefore be amended accordingly.
recital 19recital 19
(19) Commission Implementing Regulation (EU) 2021/745 ( 11 ) extended the approval period of bifenazate to 31 July 2022 in order to allow the renewal process to be completed before the expiry of the approval period of that active substance. However, given that a decision on renewal has been taken ahead of that extended expiry date, this Regulation shall apply as soon as possible.
recital 20recital 20
(20) The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,
Articolo 1Renewal of the approval of the active substance
The approval of the active substance bifenazate, as specified in Annex I, is renewed subject to the conditions and restrictions laid down in that Annex.
Articolo 2Amendments to Implementing Regulation (EU) No 540/2011
The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with Annex II to this Regulation.
Articolo 3Entry into force and date of application
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .
It shall apply from 1 July 2022.
Allegato IANNEX I
Common Name, Identification Numbers IUPAC Name Purity ( 1 ) Date of approval Expiration of approval Specific provisions Bifenazate 149877-41-8 736 isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinoformate 980 g/kg Toluene is of toxicological concern and must not exceed 0,7 g/kg in the technical material. 1 July 2022 30 June 2037 Only uses on non-edible crops in permanent greenhouses shall be authorised. For the implementation of the uniform principles, as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the renewal report on bifenazate, and in particular Appendices I and II thereof, shall be taken into account. In this overall assessment Member States shall pay particular attention to: — the protection of operators and workers, ensuring that conditions of use include the application of adequate personal protective equipment; — the risk to bees and bumble bees released for pollination in permanent greenhouses. Conditions of use shall include risk mitigation measures, where appropriate. The applicant shall submit by 24 May 2024 to the Commission, the Member States and the Authority confirmatory information as regards points 3.6.5 and 3.8.2 of Annex II to Regulation (EC) No 1107/2009, as amended by Regulation (EU) 2018/605, in particular an updated assessment of the information submitted previously and, where relevant, further information to confirm the absence of endocrine activity.
Allegato IIANNEX II
The Annex to Implementing Regulation (EU) No 540/2011 is amended as follows:
(1) in Part A, entry 109 on bifenazate is deleted;
(2) in Part B, the following entry is added: No. Common Name, Identification Numbers IUPAC Name Purity ( 1 ) Date of approval Expiration of approval Specific provisions ‘ 152 Bifenazate 149877-41-8 736 isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinoformate 980 g/kg Toluene is of toxicological concern and must not exceed 0,7 g/kg in the technical material. 1 July 2022 30 June 2037 Only uses on non-edible crops in permanent greenhouses shall be authorised. For the implementation of the uniform principles, as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the renewal report on bifenazate, and in particular Appendices I and II thereof, shall be taken into account. In this overall assessment Member States shall pay particular attention to: — the protection of operators and workers, ensuring that conditions of use include the application of adequate personal protective equipment; — the risk to bees and bumble bees released for pollination in permanent greenhouses. Conditions of use shall include risk mitigation measures, where appropriate. The applicant shall submit by 24 May 2024 to the Commission, the Member States and the Authority confirmatory information as regards points 3.6.5 and 3.8.2 of Annex II to Regulation (EC) No 1107/2009, as amended by Regulation (EU) 2018/605, in particular an updated assessment of the information submitted previously and, where relevant, further information to confirm the absence of endocrine activity.’